Produktinformation
- N-[2-[[[5-[(Dimethyloxidoamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine
- 1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-, N-oxide
- N-[2-[[[5-[(Dimethyloxidoamino)methyl]-2-furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-1,1-ethenediamine
- 1,1-Ethenediamine, N-[2-[[[5-[(dimethyloxidoamino)methyl]-2-furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-
Ranitidine N-oxide is a metabolite of ranitidine, which is an H2 receptor antagonist. It has been shown that the pharmacological effects of ranitidine are due to the parent drug and its metabolites, including ranitidine N-oxide. This metabolite can be detected in human liver and urine samples. Ranitidine N-oxide is formed from the parent drug through chemical reactions that occur in the liver and it has been shown to have clinical relevance for patients with cirrhosis or chronic viral hepatitis. Ranitidine N-oxide also competes with caffeine for binding sites on proteins in the liver, thereby reducing caffeine's ability to inhibit gastric acid secretion. The optimum concentration of ranitidine N-oxide in an assay sample is 100 ng/mL, although this concentration may vary depending on the type of sample being analyzed (e.g., serum or urine). Chromatography is used to separate compounds before they are analyzed by mass spectrometry, while analytical
